Fractyl Health (NASDAQ:GUTS) outlined upcoming clinical and regulatory milestones for its lead obesity and diabetes program, Revita, during a presentation at the BofA Annual Healthcare Conference, where executives described the therapy as a potential non-drug option for maintaining weight loss after GLP-1 use.
Harith Rajagopalan, Fractyl Health’s co-founder and chief executive officer, said Revita is a catheter-based duodenal mucosal resurfacing technology designed to ablate what the company believes is “duodenal dysfunction” tied to obesity and type 2 diabetes. He said the company’s lead indication is focused on weight-loss maintenance after patients discontinue GLP-1 medicines.
Revita Data Readouts Expected Over Next Six Months
Rajagopalan said Fractyl expects three major catalysts from its weight-maintenance program over the next six months. The company expects 12-month data from the open-label REVEAL-1 cohort in the second quarter. Those patients lost more than 20% of their body weight on a GLP-1 before entering the study, he said.
Rajagopalan said Fractyl expects patients who discontinue GLP-1 therapy to regain roughly 15% of total body weight at one year based on available data. He said a result showing less than 7.5% weight regain at one year would be “a phenomenal result.”
The company also expects 12-month data in the third quarter from the REMAIN-1 midpoint cohort, a randomized study of 45 patients assigned two-to-one to Revita or sham. Rajagopalan said cutting expected weight regain by half in the Revita arm, to 7.5% or less, would represent a “very compelling clinical profile” in a prospective sham-controlled study.
Fractyl also expects a six-month co-primary endpoint from the pivotal REMAIN-1 cohort in early fourth quarter. Rajagopalan said the totality of the data would support a potential de novo regulatory filing by the end of the year.
Regulatory Pathway and Safety Profile
Rajagopalan said the FDA has reviewed Fractyl’s safety data and placed Revita on a class II, low-to-moderate risk de novo pathway rather than a higher-risk PMA route. He said the regulatory standard for the pathway is based on the totality of clinical evidence and a “reasonable assurance of safety and effectiveness.”
He said the REMAIN-1 pivotal study is a “prospective randomized double-blinded sham controlled” trial and described it as the largest sham-controlled study conducted in endoscopy. Rajagopalan said Fractyl has not seen late adverse events and said the procedural risk appears time-limited, unlike chronic pharmacotherapy.
On the question of ablation length, Rajagopalan said patients receiving more than 14 centimeters of ablation in the company’s first sham-controlled weight-maintenance study had better protection from weight regain than those receiving less. He said there has not appeared to be a correlation between ablation length and safety or tolerability.
Commercial Strategy Focuses on Endoscopy Centers
If Revita is approved, Rajagopalan said Fractyl believes it can pursue a targeted commercial model focused on the top 100 to 200 centers in the United States. He said the company has built relationships with GI endoscopists through its pivotal program and that many physicians involved are familiar with Revita.
Rajagopalan said Revita was designed to fit into existing endoscopy workflows, specifically suites with fluoroscopy capability. He said physicians have indicated that they could shift lower-margin procedures to colleagues to make room for higher-value procedures such as Revita, if reimbursed.
He also said Fractyl has signed a letter of intent with Everself, formerly called Bariendo, a nationwide provider of bariatric and metabolic endoscopy services. Rajagopalan said consumer outreach by such centers suggests demand from GLP-1 users looking for an “off-ramp.”
Rejuva Program Cleared for First-in-Human Study
Rajagopalan also discussed Rejuva, which he described as a “smart, potentially one-and-done GLP-1 pancreatic gene therapy.” He said Fractyl recently received regulatory clearance in the Netherlands to begin a first-in-human study.
He said the target product profile for Rejuva in type 2 diabetes is disease remission, which he said does not currently exist as a therapeutic goal in the market. Fractyl expects to potentially dose first patients pending site activation, with preliminary data expected in the back half of 2026. Rajagopalan said early safety, feasibility and tolerability signals could emerge within one to two weeks of treatment, while continuous glucose monitoring data could provide initial pharmacodynamic insights at roughly eight to 12 weeks.
Cash Runway Extends Into 2027
Lara Smith Weber, Fractyl Health’s chief financial officer, said the company ended the first quarter with $63.2 million in cash. She said Fractyl is funded into 2027, including through the expected fourth-quarter pivotal Revita data readout and a potential de novo filing.
Smith Weber said the company expects to have about five to six months of cash on hand at that point and is evaluating options to preserve flexibility for a future funding event.
About Fractyl Health (NASDAQ:GUTS)
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.
